A. Hartry

发表

Commensurability in memory for frequency

Douglas L. Hintzman, D. L. Hintzman, A. Hartry, 1990 .

Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis

H. Fillit, R. Baker, A. Hartry, 2019, BMC Neurology.

Emotional expectancy: brain electrical activity associated with an emotional bias in interpreting life events.

M Liotti, G F Potts, D M Tucker, 1996, Psychophysiology.

Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases.

M. Broder, E. Chang, M. Greene, 2018, Clinical therapeutics.

Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder

M. Broder, E. Chang, M. Greene, 2018, Journal of medical economics.

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting

C. Lançon, P. Llorca, D. Zighed, 2017, Journal of market access & health policy.

All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics

M. Broder, E. Chang, M. Greene, 2018, Current medical research and opinion.

Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data

M. Broder, I. Yermilov, E. Chang, 2018, Advances in Therapy.

Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia

A. Hartry, M. Aigbogun, R. Halpern, 2018, International journal of geriatric psychiatry.

Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review

H. Fillit, M. Grundman, M. Ladouceur, 2020, Journal of Alzheimer's disease : JAD.

Patient preference for early onset of efficacy of preventive migraine treatments

M. Bøg, P. Winner, A. Hartry, 2022, Headache.

A Continuous Publication, Open Access, Peer-reviewed Journal Pharmacoeconomic Comparison of Aripiprazole Once-monthly and Paliperidone Palmitate from a Head-to-head Clinical Trial in Schizophrenia: a Us Analysis

R. Baker, A. Hartry, A. Eramo, 2022 .

Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics.

C. Karson, S. Seabury, A. Hartry, 2016, Psychiatric services.

Item effects in recognition and fragment completion: Contingency relations vary for different subsets of words.

Douglas L. Hintzman, D. L. Hintzman, A. Hartry, 1990 .

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder

M. Greene, A. Hartry, C. Burudpakdee, 2019, ClinicoEconomics and outcomes research : CEOR.

CEOR_A_220007 741..755

M. Greene, A. Hartry, C. Burudpakdee, 2019 .

Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease

L. Callahan, H. Krasa, D. Oberdhan, 2023, Neurology and Therapy.

Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data

M. Broder, E. Chang, M. Greene, 2019, Current medical research and opinion.

Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.

M. Sussman, A. Hartry, M. Aigbogun, 2017, Journal of affective disorders.

Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data

M. Broder, E. Chang, M. Greene, 2018, Advances in Therapy.

A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients

H. Fillit, O. Baser, P. Neumann, 2017, Neurology and Therapy.

Institutionalization risk and costs associated with agitation in Alzheimer's disease

R. Baker, A. Hartry, M. Gauthier-Loiselle, 2019, Alzheimer's & dementia.

Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder

M. Greene, A. Hartry, C. Burudpakdee, 2018, Journal of medical economics.

Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes

L. Callahan, H. Krasa, S. Wronski, 2020, Alzheimer's Research & Therapy.

Chronic pain and pain medication use in chronic obstructive pulmonary disease. A cross-sectional study.

A. V. Von Worley, A. Hartry, M. Roberts, 2013, Annals of the American Thoracic Society.

Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications

C. Lançon, P. Llorca, T. Brown, 2017, BMC Psychiatry.

Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course

A. Brooks, R. Baker, A. Hartry, 2019, International Psychogeriatrics.

Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder.

M. Broder, E. Chang, M. Greene, 2019, Journal of comparative effectiveness research.

Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder

M. Broder, I. Yermilov, E. Chang, 2018, Journal of medical economics.

Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.

M. Broder, I. Yermilov, E. Chang, 2019, Clinical therapeutics.

Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia

H. Fillit, M. Ganz, S. Verma, 2020, JAMA network open.

A Comparison of Daily Average Consumption Of Oxycodone Controlled Release (OxyContin CR) And Oxymorphone Extended Release (Opana ER) In Patients With Low Back Pain.

R. Puenpatom, S. Szeinbach, R. Ben-Joseph, 2011, P & T : a peer-reviewed journal for formulary management.